REGN ▲ +2.0% - Regeneron Pharmaceuticals, Inc. $REGN Regeneron Q3 earnings beat — Revenue $5.1B vs $4.54B expected, up 36% YoY — Adj. EPS $20.07 vs $16.24 expected, up 70% YoY — Dupixent global net sales $6.5B, up 35% YoY — EYLEA HD U.S. sales $699M, up 62% YoY — Raised FY26 gross margin guide to 86% from 84% to 85% 30-OCT-2026 06:34 AM ET